Diagnostic Potential of Serum VEGF-D for Lymphangioleiomyomatosis
Authors:
- Lisa R. YoungLYLisa R. Young
- Yoshikazu InoueYIYoshikazu Inoue
- Francis X. McCormackFMFrancis X. McCormack
- 10 January 2008
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 358 (2) , 199-200
Abstract
To the Editor: Lymphangioleiomyomatosis is a rare, progressive, frequently fatal cystic lung disease that affects women almost exclusively.1,2 It occurs in up to 40% of women with the tuberous sclerosis complex, a tumor-suppressor syndrome associated with seizures, cognitive impairment, and hamartomas in multiple organs, and can also occur in a nonheritable sporadic form that involves only the lung, lymphatics, and kidney.3 The presence of the tuberous sclerosis complex or fat-containing renal hamartomas called angiomyolipomatas in a woman with characteristic cystic changes on a high-resolution computed tomographic (CT) scan of the chest is considered to be diagnostic of lymphangioleiomyomatosis. However, . . .Keywords
This publication has 5 references indexed in Scilit:
- Molecular Pathogenesis of LymphangioleiomyomatosisAmerican Journal of Respiratory Cell and Molecular Biology, 2007
- The Tuberous Sclerosis ComplexNew England Journal of Medicine, 2006
- Vascular Endothelial Growth Factor-D Is Increased in Serum of Patients with LymphangioleiomyomatosisLymphatic Research and Biology, 2006
- LymphangioleiomyomatosisEuropean Respiratory Journal, 2006
- Chronic Cystic Lung Disease: Diagnostic Accuracy of High-Resolution CT in 92 PatientsAmerican Journal of Roentgenology, 2003